Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy EyeGate Pharmaceuticals stock | $3.65

Own EyeGate Pharmaceuticals stock in just a few minutes.

Fact checked

EyeGate Pharmaceuticals, Inc is a biotechnology business based in the US. EyeGate Pharmaceuticals shares (EYEG) are listed on the NASDAQ and all prices are listed in US Dollars. EyeGate Pharmaceuticals employs 10 staff and has a market cap (total outstanding shares value) of USD$32.7 million.

How to buy shares in EyeGate Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for EyeGate Pharmaceuticals. Find the stock by name or ticker symbol: EYEG. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until EyeGate Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$3.65, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of EyeGate Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of EyeGate Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

EyeGate Pharmaceuticals share price

Use our graph to track the performance of EYEG stocks over time.

EyeGate Pharmaceuticals shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$3.65
52-week rangeUSD$3.2 - USD$12.89
50-day moving average USD$3.7691
200-day moving average USD$4.1924
Wall St. target priceUSD$14.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.274

Buy EyeGate Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy EyeGate Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

EyeGate Pharmaceuticals price performance over time

Historical closes compared with the close of $3.65 from 2020-12-09

1 week (2021-01-09) N/A
1 month (2020-12-18) 2.24%
3 months (2020-10-16) -2.67%
6 months (2020-07-17) -28.01%
1 year (2020-01-17) -46.72%
2 years (2019-01-18) 618.50%
3 years (2018-01-18) 204.17%
5 years (2016-01-16) N/A

EyeGate Pharmaceuticals financials

Gross profit TTM USD$-2,203,357
Return on assets TTM -53.94%
Return on equity TTM -149.97%
Profit margin 0%
Book value $1.288
Market capitalisation USD$32.7 million

TTM: trailing 12 months

Shorting EyeGate Pharmaceuticals shares

There are currently 8,910 EyeGate Pharmaceuticals shares held short by investors – that's known as EyeGate Pharmaceuticals's "short interest". This figure is 4.4% down from 9,320 last month.

There are a few different ways that this level of interest in shorting EyeGate Pharmaceuticals shares can be evaluated.

EyeGate Pharmaceuticals's "short interest ratio" (SIR)

EyeGate Pharmaceuticals's "short interest ratio" (SIR) is the quantity of EyeGate Pharmaceuticals shares currently shorted divided by the average quantity of EyeGate Pharmaceuticals shares traded daily (recently around 37125). EyeGate Pharmaceuticals's SIR currently stands at 0.24. In other words for every 100,000 EyeGate Pharmaceuticals shares traded daily on the market, roughly 240 shares are currently held short.

However EyeGate Pharmaceuticals's short interest can also be evaluated against the total number of EyeGate Pharmaceuticals shares, or, against the total number of tradable EyeGate Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case EyeGate Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 EyeGate Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0019% of the tradable shares (for every 100,000 tradable EyeGate Pharmaceuticals shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against EyeGate Pharmaceuticals.

Find out more about how you can short EyeGate Pharmaceuticals stock.

EyeGate Pharmaceuticals share dividends

We're not expecting EyeGate Pharmaceuticals to pay a dividend over the next 12 months.

Have EyeGate Pharmaceuticals's shares ever split?

EyeGate Pharmaceuticals's shares were split on a 1:15 basis on 30 August 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your EyeGate Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for EyeGate Pharmaceuticals shares which in turn could have impacted EyeGate Pharmaceuticals's share price.

EyeGate Pharmaceuticals share price volatility

Over the last 12 months, EyeGate Pharmaceuticals's shares have ranged in value from as little as $3.2 up to $12.89. A popular way to gauge a stock's volatility is its "beta".

EYEG.US volatility(beta: 1.15)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while EyeGate Pharmaceuticals's is 1.1512. This would suggest that EyeGate Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

EyeGate Pharmaceuticals overview

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye in the United States. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds, defects, and epitheliopathies, as well as for re-epithelization of the ocular surface. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and anterior uveitis; and Eyegate II drug delivery system. The company has license agreements with the University of Miami School of Medicine; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site